New Rochelle, NY, February 6, 2014--The ability to reprogram adult cells so they return to an undifferentiated, pluripotent state--much like an embryonic stem cell--is enabling the development of promising new cell therapies. Accelerating progress in this field will depend on identifying factors that promote pluripotency, such as the Brg1 protein described in a new study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.
In "BRG1 Is Required to Maintain Pluripotency of Murine Embryonic Stem Cells," Nishant Singhal and coauthors, Max Planck Institute for Molecular Biomedicine, Münster, and University of Münster, Germany, demonstrate the critical role the Brg1 protein plays in regulating genes that are part of a network involved in maintaining the pluripotency of embryonic stem cells. This same network is the target for methods developed to reprogram adult somatic cells.
"This work further clarifies the role of the Brg1 containing BAF complex in regulating pluripotency and has important implications for all cellular reprogramming technologies," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.
About the JournalBioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including, DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc.
140 Huguenot St.New Rochelle, NY 10801-5215